Drug Trial Radar · NCT01984749
Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy
Last checked: Nov 20, 2026Latest source record: Aug 26, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Nov 2013
Primary completion
Oct 2017
Sponsor
- Lead sponsor
- Freed Study GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Teijin Pharma Limited
- First posted
- Nov 15, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate the effect of febuxostat in preventing cerebral and cardiorenovascular events in elderly patients with hyperuricemia who are at risk for cerebral and cardiorenovascular disease.
Conditions
- Hyperuricemia
Interventions
FebuxostatDrug
Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed. 1. The starting dose of the investigational product (febuxostat) will be 10 mg/day. 2. The dose will be increased to 20 mg/day at Week 4. 3. The aim is to increase the dose to 40 mg/day at Week 8.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development of cerebral or cardiorenovascular events and all deathsTime frame: Enrollment through Month 36
Locations
140 sites in 1 country. Site status is shown where the registry gives one.
Hiramitsu Heart Clinic
Nagoya, Aichi-ken, Japan
Ogawa-naika Clinic
Nagoya, Aichi-ken, Japan
Shakaiiryohojin Kojunkai Daido Hospital
Nagoya, Aichi-ken, Japan
Honjo Daiichi Hospital
Yurihonjō, Akita, Japan
Iriyouhoujin Siyadan Yanagisawakai Yanagisawaiin
Matsudo, Chiba, Japan
Matsuno Medical Clinic
Iyo-gun, Ehime, Japan
Ishite Matsumoto Naika Junkanki Clinic
Matsuyama, Ehime, Japan
Ehime Medical CO-OP Izumigawa Clinic
Niihama, Ehime, Japan
Hanaoka IC Clinic
Buzen, Fukuoka, Japan
Otonari Clinic
Chikushino-shi, Fukuoka, Japan
Saku Hospital
Fukuoka, Fukuoka, Japan
Tohaya Iin
Fukuoka, Fukuoka, Japan
Medical Cooperation Toseikai Goto Clinic
Kitakyushu, Fukuoka, Japan
ONGA NAKAMA Medical Association ONGA Hospital
Onga-gun, Fukuoka, Japan
Southern Tohoku Research Institute For Neuroscience Southern Tohoku Medical Clinic
Kōriyama, Fukushima, Japan
Iryohojin Shadan Seijinkai Kawade Iin
Gifu, Gifu, Japan
Kawai Naika Clinic
Gifu, Gifu, Japan
Miwa Clinic: Gastroenterology Hepatology
Gifu, Gifu, Japan
Sagou Clinic
Gifu, Gifu, Japan
Sasaki Clinic
Gifu, Gifu, Japan
Takai Clinic
Gifu, Gifu, Japan
Takeda Clinic
Gifu, Gifu, Japan
Totani Medical Clinic
Gifu, Gifu, Japan
Noda Clinic
Ibi, Gifu, Japan
Sunomata Clinic
Ōgaki, Gifu, Japan
Tsurugaya Hospital
Isesaki, Gunma, Japan
Nakano Clinic
Shibukawa, Gunma, Japan
Iryouhoujinn Makikai Makibyouinn
Takasaki, Gunma, Japan
Shigenobu Clinic
Miyoshi, Hiroshima, Japan
Keiyukai Yoshida Hospital
Asahikawa, Hokkaido, Japan
Matsui Naika Clinic
Asahikawa, Hokkaido, Japan
Omiya Clinic
Asahikawa, Hokkaido, Japan
Miyanomori Memorial Hospital
Sapporo, Hokkaido, Japan
Okamoto Naika Clinic
Sapporo, Hokkaido, Japan
River Side Clinic
Sapporo, Hokkaido, Japan
Katsuya Iin
Amagasaki, Hyōgo, Japan
Kousei Hospital
Himeji, Hyōgo, Japan
Nakatani Hospital
Himeji, Hyōgo, Japan
Harima Clinic
Kakogawa, Hyōgo, Japan
Kusunose Surgery Clinic
Kobe, Hyōgo, Japan
Showing 40 of 140 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.